Brief: Rhythm Pharmaceuticals Announces Preliminary Data From Exploratory Phase 2 Trial That Showed Setmelanotide Demonstrated Positive Efficacy Signal In Prader-Willi Syndrome
11/12/2025 12:34
Dec 11 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O: RHYTHM PHARMACEUTICALS ANNOUNCES PRELIMINARY DATA FROM EXPLORATORY PHASE 2 TRIAL THAT SHOWED SETMELANOTIDE DEMONSTRATED POSITIVE EFFICACY SIGNAL IN PRADER-WILLI SYNDROME RHYTHM PHARMACEUTICALS INC - PLANS PHASE 3 TRIAL FOR SETMELANOTIDE IN PWS RHYTHM PHARMACEUTICALS INC: SAFETY AND TOLERABILITY RESULTS HAVE BEEN CONSISTENT WITH SETMELANOTIDE'S WELL-ESTABLISHED CLINICAL PROFILE RHYTHM PHARMACEUTICALS INC - SETMELANOTIDE SHOWS BMI AND HYPERPHAGIA REDUCTIONS IN PWS Source text: ID:nGNX88c91t Further company coverage: RYTM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand